Skip to content
Supplemental

Capital expenditures incurred but not yet paid

Medline, Inc. Capital expenditures incurred but not yet paid remained flat by 0.0% to $14.5M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 16.0%, from $12.5M to $14.5M. Over 2 years (FY 2023 to FY 2025), Capital expenditures incurred but not yet paid shows an upward trend with a 52.3% CAGR.

Analysis

StatementCash Flow Statement
SectionSupplemental
First reportedQ1 2023
Last reportedQ4 2025Feb 25, 2026
Metric ID: nflx_capex_incurred_not_paid

Historical Data

3 years
 FY'23FY'24FY'25
Value$25M$50M$58M
YoY Change+100.0%+16.0%
Range$25M$58M
CAGR+52.3%
Avg YoY Growth+58.0%
Median YoY Growth+58.0%
Current Streak2+ years growth

Frequently Asked Questions

What is Medline, Inc. 's capital expenditures incurred but not yet paid?
Medline, Inc. (MDLN) reported capital expenditures incurred but not yet paid of $14.5M in Q4 2025.
How has Medline, Inc. 's capital expenditures incurred but not yet paid changed year-over-year?
Medline, Inc. 's capital expenditures incurred but not yet paid increased by 16.0% year-over-year, from $12.5M to $14.5M.
What is the long-term trend for Medline, Inc. 's capital expenditures incurred but not yet paid?
Over 2 years (2023 to 2025), Medline, Inc. 's capital expenditures incurred but not yet paid has grown at a 52.3% compound annual growth rate (CAGR), from $25M to $58M.